Tafamidis in the Treatment of ATTR-related Cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) is caused by the myocardial extracellular deposition of amyloid fibrils formed from the dissociation of TTR tetramer into monomers. The rate-limiting step in TTR amyloidogenesis is the dissociation of the TTR tetramer into monomers: Tafamidis is an effective TTR-stabilizer in its native homotetrameric structure. Tafamidis is a safe and effective drug in reducing symptoms, hospitalization and mortality in accurately selected patients affected by hereditary and wild-type transthyretin amyloid cardiomyopathy.

Source: Heart Failure Clinics - April 12, 2024 Category: Cardiology Authors: Teresa Maria Capovilla, Andrea Lalario, Maddalena Rossi, Aldostefano Porcari, Alberto Aimo, Giuseppe Limongelli, Michele Emdin, Marco Merlo, Gianfranco Sinagra Source Type: research